Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.

@article{Bae2010SusceptibilityOT,
  title={Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.},
  author={Andrew S Bae and S. C. Sun and Xiaoping Qi and Xiaowu Chen and Karin S Ku and Angela S Worth and Kelly A. Wong and Jeanette L Harris and Michael D. Miller and Hongmei Mo},
  journal={Antimicrobial agents and chemotherapy},
  year={2010},
  volume={54 12},
  pages={5288-97}
}
In order to assess the natural variation in susceptibility to hepatitis C virus (HCV) NS3 protease inhibitors (PIs) among untreated HCV patient samples, the susceptibilities of 39 baseline clinical isolates were determined using a transient-replication assay on a panel of HCV PIs, including two α-ketoamides (VX-950 and SCH-503034) and three macrocyclic inhibitors (MK-7009, ITMN-191, and TMC-435350). Some natural variation in susceptibility to all HCV PIs tested was observed among the baseline… CONTINUE READING